China’s biopharma commands $30 billion in oncology licensing deals, triples US output in 2024 Read more
Large pharma drug licensing from China reaches record high at 28 per cent in 2024, reveals GlobalData Read more
India’s reputation as the “Pharmacy to the World” is potentially under threat, substandard imports of IPA add to the quality burden Read more
Eisai and Biogen’s Leqembi launch in China marks turning point in Alzheimer’s treatment, says GlobalData Read more